Aligos Therapeutics Q2 EPS $(0.79) Beats $(0.81) Estimate

Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.81) by 2.47 percent.

byBill Haddad

August 5, 2021

1 minute read

Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.81) by 2.47 percent.

Albireo Pharma Shares Plunge After Q2 Results Misses Profit Estimates

By Akanksha Bakshi

Today, 2:14 AM

Albireo Pharma Inc (NASDAQ: ALBO) reported second-quarter revenue of $8.21 million, with product revenue of $5.89 million, an increase of 238%…

ALBO

$1000 Invested In Copart 5 Years Ago Would Be Worth This Much Today

By Benzinga Insights

Today, 2:14 AM

Copart (NASDAQ:CPRT) has outperformed the market over the past 5 years by 19.98% on an annualized basis producing an average annual return of 29.72%. Currently, Copart has a market capitalization of $28.27 billion.

CPRT

Jefferies Initiates Coverage On European Wax Center with Buy Rating, Announces Price Target of $33

By Benzinga Newsdesk

Today, 2:14 AM

Jefferies analyst Randal Konik initiates coverage on European Wax Center (NASDAQ:EWCZ) with a Buy rating and announces Price Target of $33.

EWCZ

News

ScanSource Insights: Return On Capital Employed

By Benzinga Insights

Today, 2:14 AM

ScanSource (NASDAQ:SCSC) posted Q3 earnings of $19.44 million, an increase from Q2 of 13.46%. Sales dropped to $729.87 million, a 9.99% decrease between quarters. In Q2, ScanSource earned $17.13 million, whereas sales reached $810.90 million.

SCSC

Aligos Therapeutics Q2 EPS $(0.79) Beats $(0.81) Estimate

Related Posts

Albireo Pharma Shares Plunge After Q2 Results Misses Profit Estimates

$1000 Invested In Copart 5 Years Ago Would Be Worth This Much Today

Jefferies Initiates Coverage On European Wax Center with Buy Rating, Announces Price Target of $33

ScanSource Insights: Return On Capital Employed